Skip to main content
UniHealth

Doctor search

Christopher F Barnett, MD

Cardiovascular Disease (Cardiology) · San Francisco

NPI 1538127717

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
3
Since medical school
25 years
Northwestern University Feinberg Medical School, 2001

Offices

3 locations · University of California San Francisco · Regents of the University of California

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barnett’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A99520 · Current

Licensed to practise in California · since 2007 · expires 2028-11-30 · Northwestern University Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Advanced Heart Failure and Transplant
  • American Board of Internal Medicine - Cardiovascular Disease
  • American Board of Internal Medicine - Critical Care Medicine

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$65,679

Medicare paid this office $65,679 for 163 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Critical care, first 30-74 minutes98$45,862$183
Critical care, each additional 30 minutes35$7,502$91
Long return visit (40+ min)22$4,609$121
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$2,000$105
Insertion of artery tube for blood sampling or infusion through skin11$482$37
See all 6 services
Every Original Medicare service billed
Critical care, first 30-74 minutes98$45,862$183
Critical care, each additional 30 minutes35$7,502$91
Long return visit (40+ min)22$4,609$121
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$2,000$105
Insertion of artery tube for blood sampling or infusion through skin11$482$37
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's16$326$15

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Insertion of non-tunneled central venous tube for infusion (5 years or older)1715–14––
Insertion of artery tube for blood sampling or infusion through skin12––––13

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

163 Original Medicare patients in 2024. Average age 70 · Under 65 23% · 85 and older 13% · Women 46% · Also on Medicaid 57% · Health risk score 3.56. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.

Conditions among them: High blood pressure 75% · Heart failure 75% · Coronary heart disease 68% · Chronic kidney disease 68% · Diabetes 59% · Atrial fibrillation 49% · COPD 31% · Depression 29% · Stroke 26% · Dementia 21% · Cancer 15%.

The office billed $530,299, Medicare allowed $82,721 and paid $65,679; for 473 services of 23 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024163473703.56$530,299$65,679
2023177699712.71$865,081$107,645
2022132437723.05$479,689$60,977
2021214529712.72$392,381$87,636
2020416921723.31$395,812$122,823
20198731,569722.91$434,687$139,299
20185411,160723.07$504,943$169,576
2017442958723.02$428,229$136,845
2016157323722.47$157,183$54,137
20151620662.68$4,558$906
2014186298672.18$112,407$21,376
2013454753701.94$261,015$48,155

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Critical care, first 30-74 minutes115$82,426$184
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes40$6,539$105
Long return visit (40+ min)25$5,597$124
Critical care, each additional 30 minutes26$5,294$93
Initial hospital care with moderate level of medical decision making at least 75 minutes12$1,845$154

2022: 6 services

Original Medicare services billed in 2022
Critical care, first 30-74 minutes74$39,923$186
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes52$8,195$90
Critical care, each additional 30 minutes16$3,480$94
New patient visit (60+ min)12$1,956$163
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes14$1,220$87
Insertion of non-tunneled central venous tube for infusion (5 years or older)11$1,019$73

2021: 4 services

Original Medicare services billed in 2021
Critical care, first 30-74 minutes135$66,824$193
Long return visit (40+ min)54$9,853$120
Long return visit (40+ min)11$2,342$167
New patient visit (60+ min)11$1,692$154

2020: 9 services

Original Medicare services billed in 2020
Critical care, first 30-74 minutes202$93,010$194
Long return visit (40+ min)72$11,602$96
New patient visit (60+ min)19$2,770$146
Dialysis procedure including 1 evaluation12$1,943$78
Telephone medical discussion with physician, 21-30 minutes22$1,841$68
Long return visit (40+ min)11$1,651$118
Insertion of non-tunneled central venous tube for infusion (5 years or older)15$1,136$76
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only124$1,085$7
Critical care, each additional 30 minutes11$1,041$95

2019: 8 services

Original Medicare services billed in 2019
Critical care, first 30-74 minutes249$104,888$190
Long return visit (40+ min)75$13,403$96
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only583$5,412$7
Long return visit (40+ min)21$3,518$126
New patient visit (60+ min)22$3,198$145
Critical care, each additional 30 minutes17$2,143$97
Insertion of non-tunneled central venous tube for infusion (5 years or older)15$1,289$76
Insertion of artery tube for blood sampling or infusion through skin11$470$39

2018: 5 services

Original Medicare services billed in 2018
Critical care, first 30-74 minutes329$143,766$190
Long return visit (40+ min)72$11,697$97
New patient visit (60+ min)20$2,974$149
Long return visit (40+ min)11$1,692$130
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only129$1,215$7

2017: 4 services

Original Medicare services billed in 2017
Critical care, first 30-74 minutes277$116,302$179
Long return visit (40+ min)62$8,345$91
Long return visit (40+ min)33$4,695$115
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only95$706$7

2016: 3 services

Original Medicare services billed in 2016
Critical care, first 30-74 minutes105$43,766$191
Long return visit (40+ min)22$3,608$129
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function14$774$55

2015: 1 service

Original Medicare services billed in 2015
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function14$797$57

2014: 6 services

Original Medicare services billed in 2014
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function122$7,140$58
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,891$181
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$2,321$93
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,737$64
Ultrasound of heart blood flow, valves and chambers, follow-up12$79$7
Ultrasound of heart with color-depicted blood flow, rate and valve function14$42$3

2013: 11 services

Original Medicare services billed in 2013
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function301$17,149$54
Initial hospital care with moderate level of medical decision making at least 75 minutes54$9,972$175
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes40$6,287$62
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$4,965$89
Hospital discharge day management, 30 minutes or less32$2,177$64
Long return visit (40+ min)11$1,721$96
Ultrasound of heart, follow-up23$489$20
Ultrasound of heart blood flow, valves and chambers, follow-up28$169$6
Ultrasound of heart with color-depicted blood flow, rate and valve function36$113$3
Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician11$102$9
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only12$95$6

Medicaid work

$35,782 in 2024

Medicaid paid $35,782 for 232 billed services this clinician did in 2024, up to 18 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes215$33,358
Long return visit (40+ min)17$2,424
Medicaid work by year
2024232218$35,782
2023151117$24,681
2022142215$18,638
202130112$2,767
20202192118$9,958
20196723135$10,179
2018125277$3,086
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes151$24,681

2022

Largest Medicaid services in 2022
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes103$15,050
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES39$3,589

2021

Largest Medicaid services in 2021
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes30$2,767

2020

Largest Medicaid services in 2020
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes80$9,299
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only139$659

2019

Largest Medicaid services in 2019
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes64$6,592
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only581$2,560
Long return visit (40+ min)27$1,027

2018

Largest Medicaid services in 2018
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes20$2,668
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only105$418

Drugs they prescribed that Part D paid

$2,565,315

Pharmacies billed $2,565,315 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 415) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.

208 generic and 207 brand-name prescriptions · $2,565,315 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Opsumit86$1,068,062$12,419
Uptravi32$730,267$22,821
Winrevair17$234,344$13,785
Orenitram Er27$137,299$5,085
Ambrisentan32$101,050$3,158
See all 12 drugs
Every Part D drug this clinician prescribed
Opsumit86$1,068,062$12,419
Uptravi32$730,267$22,821
Winrevair17$234,344$13,785
Orenitram Er27$137,299$5,085
Ambrisentan32$101,050$3,158
Adcirca12$48,663$4,055
Tadalafil68$43,963$647
Ozempic12$11,311$943
Sildenafil Citrate16$5,181$324
Spironolactone24$404$17
Torsemide14$250$18
Furosemide14$101$7

Year by year

Part D prescribing by year
2024415330% (0)50%$2,565,315
2023166250% (0)None$931,093
2022148270% (0)48%$1,590,441
2021650450% (0)49%$5,802,292
2020701490% (0)48%$4,653,995
2019651500% (0)52%$4,323,510
2018517570% (0)61%$2,594,275
2017577530% (0)57%$1,757,395
201615230None38%$185,759
20153615None44%$87,538
201437054None40%$435,690
201355177None35%$325,119

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 5 drugs

Part D drugs prescribed in 2023
Uptravi15$348,870$23,258
Opsumit24$313,097$13,046
Tadalafil37$125,698$3,397
Ambrisentan21$69,150$3,293
Spironolactone12$586$49

2022: 3 drugs

Part D drugs prescribed in 2022
Uptravi39$698,588$17,913
Orenitram Er14$570,132$40,724
Tadalafil55$69,403$1,262

2021: 9 drugs

Part D drugs prescribed in 2021
Uptravi114$2,232,259$19,581
Orenitram Er46$1,393,193$30,287
Opsumit75$867,835$11,571
Adempas55$675,388$12,280
Tadalafil201$272,546$1,356
Ambrisentan41$221,647$5,406
Adcirca14$69,997$5,000
Alyq16$27,093$1,693
Torsemide22$762$35

2020: 11 drugs

Part D drugs prescribed in 2020
Uptravi90$1,812,221$20,136
Opsumit82$886,418$10,810
Orenitram Er48$732,065$15,251
Adempas50$564,053$11,281
Tadalafil192$214,971$1,120
Letairis15$152,148$10,143
Ambrisentan34$128,104$3,768
Adcirca25$109,101$4,364
Alyq51$45,918$900
Torsemide35$1,189$34
Furosemide17$135$8

2019: 12 drugs

Part D drugs prescribed in 2019
Uptravi72$1,316,356$18,283
Opsumit85$860,354$10,122
Orenitram Er33$589,829$17,874
Adempas36$386,692$10,741
Tadalafil149$346,998$2,329
Letairis34$341,830$10,054
Adcirca67$257,863$3,849
Ambrisentan22$102,920$4,678
Alyq24$61,849$2,577
Sildenafil Citrate19$52,528$2,765
Torsemide35$1,574$45
Amlodipine Besylate12$57$5

2018: 10 drugs

Part D drugs prescribed in 2018
Uptravi33$670,211$20,309
Adcirca140$580,868$4,149
Letairis57$557,592$9,782
Opsumit47$437,666$9,312
Adempas14$138,995$9,928
Tadalafil39$125,813$3,226
Sildenafil11$2,299$209
Torsemide60$1,927$32
Spironolactone20$195$10
Lisinopril14$90$6

2017: 12 drugs

Part D drugs prescribed in 2017
Adcirca181$702,797$3,883
Letairis61$567,684$9,306
Opsumit26$260,661$10,025
Torsemide88$1,886$21
Sildenafil21$1,194$57
Bumetanide15$1,129$75
Potassium Chloride23$1,048$46
Spironolactone14$277$20
Lisinopril14$185$13
Amlodipine Besylate28$185$7
Furosemide20$148$7
Carvedilol14$84$6

2016: 4 drugs

Part D drugs prescribed in 2016
Adcirca29$95,108$3,280
Sildenafil14$2,475$177
Torsemide22$511$23
Amlodipine Besylate11$39$4

2015: 1 drug

Part D drugs prescribed in 2015
Clopidogrel12$71$6

2014: 12 drugs

Part D drugs prescribed in 2014
Letairis31$223,395$7,206
Adcirca92$196,108$2,132
Sildenafil26$8,086$311
Metoprolol17$1,357$80
Clopidogrel25$470$19
Atorvastatin12$308$26
Spironolactone20$233$12
Torsemide12$166$14
Carvedilol12$95$8
Furosemide11$74$7
Lisinopril16$71$4
Amlodipine Besylate11$33$3

2013: 14 drugs

Part D drugs prescribed in 2013
Letairis28$188,045$6,716
Adcirca46$58,548$1,273
Sildenafil11$16,216$1,474
Crestor17$2,940$173
Clopidogrel32$2,264$71
Metoprolol35$2,260$65
Atorvastatin29$1,071$37
Torsemide18$693$39
Spironolactone39$370$9
Bumetanide12$297$25
Furosemide50$279$6
Losartan22$237$11
Digox29$181$6
Lisinopril13$107$8

Money from drug and device companies

$16,824 in 2025

Industry payments by year
2025932$12,000$16,824
20241130$10,363$14,487
2023710$2,830$3,797
202248None$756
202122None$128
202024None$263
201912None$27

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Abbott LaboratoriesCardiomems$14,238
17 payments
  • Consulting for Thoratec Heartmate 3 Lvas Implant Kit · 2025-12-24 · $2,700
  • Consulting for Thoratec Heartmate 3 Lvas Implant Kit · 2025-12-24 · $1,013
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2025-12-14 · $25
  • Meals for Mediguide · 2025-10-31 · $164
  • Travel for Cardiomems · 2025-06-18 · $366
  • Consulting for 2nd Gen Centrimag Primary Console · 2025-06-17 · $1,350
  • Consulting for 2nd Gen Centrimag Primary Console · 2025-06-17 · $675
  • Consulting for Cardiomems · 2025-06-05 · $3,375
  • Consulting for Cardiomems · 2025-06-05 · $1,350
  • Consulting for Cardiomems · 2025-06-05 · $38
  • Travel for Cardiomems · 2025-06-05 · $1,856
  • Travel for Cardiomems · 2025-06-05 · $45
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2025-04-29 · $130
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2025-04-29 · $185
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2025-04-29 · $185
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2025-04-29 · $9
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2025-02-26 · $772
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Lifevest$1,500
1 payment
  • Honoraria for Lifevest · 2025-05-21 · $1,500
Merck Sharp & DohmeWinrevair$432
6 payments
  • Meals for Winrevair · 2025-08-21 · $115
  • Meals · 2025-06-12 · $81
  • Meals · 2025-05-18 · $56
  • Meals · 2025-04-30 · $101
  • Meals · 2025-04-29 · $35
  • Meals · 2025-03-30 · $44
United TherapeuticsNone$209
2 payments
  • Meals · 2025-04-29 · $61
  • Meals · 2025-02-20 · $148
AbiomedNone$135
1 payment
  • Meals · 2025-02-27 · $135
Bayer Healthcare PharmaceuticalsAdempas$127
1 payment
  • Meals for Adempas · 2025-02-26 · $127
See all 32 published payments
Every published payment
Abbott LaboratoriesConsulting · 2025-12-24Thoratec Heartmate 3 Lvas Implant Kit$2,700
Abbott LaboratoriesConsulting · 2025-12-24Thoratec Heartmate 3 Lvas Implant Kit$1,013
Abbott LaboratoriesMeals · 2025-12-14Thoratec Heartmate 3 Lvas Implant Kit$25
Abbott LaboratoriesMeals · 2025-10-31Mediguide$164
Merck Sharp & DohmeMeals · 2025-08-21Winrevair$115
Abbott LaboratoriesTravel · 2025-06-18Cardiomems$366
Abbott LaboratoriesConsulting · 2025-06-172nd Gen Centrimag Primary Console$1,350
Abbott LaboratoriesConsulting · 2025-06-172nd Gen Centrimag Primary Console$675
Merck Sharp & DohmeMeals · 2025-06-12None$81
Abbott LaboratoriesConsulting · 2025-06-05Cardiomems$3,375
Abbott LaboratoriesConsulting · 2025-06-05Cardiomems$1,350
Abbott LaboratoriesConsulting · 2025-06-05Cardiomems$38
Abbott LaboratoriesTravel · 2025-06-05Cardiomems$1,856
Abbott LaboratoriesTravel · 2025-06-05Cardiomems$45
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Honoraria · 2025-05-21Lifevest$1,500
Merck Sharp & DohmeMeals · 2025-05-18None$56
AngioDynamicsMeals · 2025-05-09Alphavac$17
Merck Sharp & DohmeMeals · 2025-04-30None$101
Merck Sharp & DohmeMeals · 2025-04-29None$35
Abbott LaboratoriesMeals · 2025-04-29Thoratec Heartmate 3 Lvas Implant Kit$130
Abbott LaboratoriesTravel · 2025-04-29Thoratec Heartmate 3 Lvas Implant Kit$185
Abbott LaboratoriesTravel · 2025-04-29Thoratec Heartmate 3 Lvas Implant Kit$185
Abbott LaboratoriesTravel · 2025-04-29Thoratec Heartmate 3 Lvas Implant Kit$9
United TherapeuticsMeals · 2025-04-29None$61
Actelion Pharmaceuticals USMeals · 2025-04-28None$118
Merck Sharp & DohmeMeals · 2025-03-30None$44
SandozMeals · 2025-03-21Treprostinil$23
AbiomedMeals · 2025-02-27None$135
Bayer Healthcare PharmaceuticalsMeals · 2025-02-26Adempas$127
Abbott LaboratoriesTravel · 2025-02-26Thoratec Heartmate 3 Lvas Implant Kit$772
United TherapeuticsMeals · 2025-02-20None$148
SandozMeals · 2025-01-22Treprostinil$26
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $14,487

Payments by company in 2024
Abbott LaboratoriesFreestyle Libre Pro$9,192
15 payments
  • Meals for 2nd Gen Centrimag Primary Console · 2024-12-27 · $133
  • Meals · 2024-11-11 · $109
  • Meals for 2nd Gen Centrimag Primary Console · 2024-10-17 · $116
  • Meals for Freestyle Libre Pro · 2024-06-07 · $29
  • Meals for Freestyle Libre Pro · 2024-06-07 · $55
  • Meals for Freestyle Libre Pro · 2024-06-07 · $82
  • Meals for Freestyle Libre Pro · 2024-06-07 · $168
  • Meals for Freestyle Libre Pro · 2024-06-07 · $92
  • Meals for Freestyle Libre Pro · 2024-06-07 · $29
  • Travel for Freestyle Libre Pro · 2024-06-07 · $341
  • Travel for Freestyle Libre Pro · 2024-06-07 · $9
  • Paid to speak or teach for Freestyle Libre Pro · 2024-05-30 · $7,425
  • Travel for Freestyle Libre Pro · 2024-05-30 · $99
  • Consulting for Freestyle Libre Pro · 2024-05-20 · $338
  • Meals for Cardiomems · 2024-04-18 · $166
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Lifevest$2,000
1 payment
  • Honoraria for Lifevest · 2024-01-17 · $2,000
PfizerNone$1,794
4 payments
  • Travel · 2024-11-15 · $281
  • Meals · 2024-11-15 · $401
  • Travel · 2024-11-15 · $281
  • Travel · 2024-11-15 · $832
AbiomedImpella$742
2 payments
  • Meals for Impella · 2024-11-16 · $142
  • Honoraria for Impella · 2024-07-08 · $600
Actelion Pharmaceuticals USOpsumit$275
2 payments
  • Meals · 2024-09-20 · $125
  • Meals for Opsumit · 2024-08-16 · $150
Impulse Dynamics (USA)Optimizer$150
1 payment
  • Meals for Optimizer · 2024-07-15 · $150
United TherapeuticsNone$142
1 payment
  • Meals · 2024-08-15 · $142
Johnson & Johnson Health Care SystemsUptravi$108
1 payment
  • Meals for Uptravi · 2024-08-17 · $108
Ethicon USMonocryl$39
1 payment
  • Meals for Monocryl · 2024-05-29 · $39
Edwards LifesciencesEdwards Sapien 3 Ultra Transcatheter Heart Valve$29
1 payment
  • Meals for Edwards Sapien 3 Ultra Transcatheter Heart Valve · 2024-12-03 · $29
MedtronicInvos$15
1 payment
  • Meals for Invos · 2024-05-30 · $15

2023: $3,797

Payments by company in 2023
Bayer Healthcare PharmaceuticalsAdempas$1,830
1 payment
  • Consulting for Adempas · 2023-06-28 · $1,830
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Lifevest$1,000
1 payment
  • Honoraria for Lifevest · 2023-05-23 · $1,000
Abbott LaboratoriesCardiomems$264
2 payments
  • Meals for Cardiomems · 2023-12-08 · $150
  • Meals for 2nd Gen Centrimag Primary Console · 2023-05-23 · $114
Actelion Pharmaceuticals USUptravi$223
2 payments
  • Meals · 2023-04-20 · $112
  • Meals for Uptravi · 2023-03-05 · $111
Merck Sharp & DohmeNone$221
2 payments
  • Meals · 2023-05-10 · $96
  • Meals · 2023-03-04 · $125
AbiomedImpella$147
1 payment
  • Meals for Impella · 2023-06-16 · $147
Getinge USA SalesCardiohelp$112
1 payment
  • Meals for Cardiohelp · 2023-05-31 · $112

2022: $756

Payments by company in 2022
Actelion Pharmaceuticals USUptravi$499
4 payments
  • Meals for Uptravi · 2022-12-09 · $121
  • Meals for Opsumit · 2022-11-15 · $132
  • Meals · 2022-08-17 · $91
  • Meals for Uptravi · 2022-04-27 · $156
Merck Sharp & DohmeNone$109
1 payment
  • Meals · 2022-03-15 · $109
United TherapeuticsTyvaso$87
1 payment
  • Meals for Tyvaso · 2022-03-16 · $87
AbiomedImpella$60
2 payments
  • Meals for Impella · 2022-08-10 · $16
  • Meals for Impella · 2022-08-06 · $44

2021: $128

Payments by company in 2021
Actelion Pharmaceuticals USUptravi$100
1 payment
  • Meals for Uptravi · 2021-10-26 · $100
AmgenRepatha$28
1 payment
  • Meals for Repatha · 2021-10-27 · $28

2020: $263

Payments by company in 2020
Boston ScientificCrossboss$182
1 payment
  • Meals for Crossboss · 2020-02-25 · $182
AmgenRepatha$81
3 payments
  • Meals for Repatha · 2020-10-22 · $32
  • Meals for Repatha · 2020-04-30 · $30
  • Meals for Corlanor · 2020-01-30 · $20

2019: $27

Payments by company in 2019
Cook MedicalNone$27
2 payments
  • Grant · 2019-01-07 · $14
  • Grant · 2019-01-07 · $14

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
BeiGene, Ltd. · A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for Covid 19 Infection and Pulmonary Distress · 2020Their institution$105,235
Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Compare the Efficacy and Safety of Sotatercept Ace-011 Versus Placebo When Added To Standard of Care for the Treatment of Pulmonary Arterial Hypertension Pah · 2022Their institution$70,467
PFIZER INC. · A Phase 1 Randomized Doubleblind Placebocontrolled Study To Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Pf07868489 in Healthy Adult Participants and Repeat Doses in Participants With Pulmonary Arterial Hypertension · 2025Their institution$62,847
BeiGene, Ltd. · Treatment of Patients Hospitalized for Covid-19 Infection and Pulmonary Distress With Zanubrutinib · 2020Their institution$30,200
Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah Mk-7962-038 · 2025Their institution$23,256
Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Compare the Efficacy and Safety of Sotatercept Ace-011 Versus Placebo When Added To Standard of Care for the Treatment of Pulmonary Arterial Hypertension Pah · 2023Their institution$18,357
BeiGene, Ltd. · A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for Covid-19 Infection and Pulmonary Distress · 2021Their institution$17,525
Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2025Their institution$17,154
Merck Sharp & Dohme Corporation · A Phase 2,3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study To Evaluate the Efficacy and Safety of Mk-5475 in Adults With Pulmonary Arterial Hypertension. · 2021Their institution$16,014
United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2019Their institution$10,923
BeiGene, Ltd. · A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for Covid-19 Infection and Pulmonary Distress · 2022Their institution$10,725
United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2020Their institution$8,836
Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2022Their institution$7,880
Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2024Their institution$7,101
United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2020Their institution$5,384
United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2019Their institution$4,995
Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2023Their institution$4,342
United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2021Their institution$4,070
Actelion Pharmaceuticals, Ltd · Opus - Ac-055-503 · 2019Their institution$500

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1538127717
Licence
CA A99520, DC MD043864, MD D0061892California A99520: Current · expires 2028-11-30
Trained
Northwestern University Feinberg Medical School, 2001 · 25 years ago
Group
University of California San Francisco · Regents of the University of California
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
DC 36932200, MD 408398900
Taxonomy
Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RA0001X (207RA0001X); Cardiology (207RC0000X); Federal specialty code 2086S0102X (2086S0102X)
Mailing address
910 Presidio Ave, Apt 3, San Francisco, CA, 94115
NPI first listed
2006-05-04
NPI last updated
2021-10-14
NPI record certified
2021-10-14

This is when the NPI record was last certified, not a medical board exam.